Loading stock data…
$1.87-0.21 (-10.10%)
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.
Alector, Inc. in the Healthcare sector is trading at $1.87 with a market capitalization of $252M. Wall Street consensus targets $3.30 (5 analysts), implying a +76.5% move over the next 12 months. The stock is currently 45% below its 52-week high of $3.40, remaining 7.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.32M↑ | $1.05M↓ | $6.24M↑ | $3.26M↓ | $7.87M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$24.39M↑ | -$24.92M↑ | -$39.57M↓ | -$37.61M↓ | -$34.14M |
| Net Income | -$22.99M↓ | -$22.93M↑ | -$37.27M↓ | -$34.67M↓ | -$30.52M |
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treatin...